Patient P-02028
Synthetic patientMETA-24 · Day 175 · 65–74 · F · baseline S14Steering view · 3DOpen companion preview
Therapy response
Declining
Tolerance
Favorable
GI state
Favorable
Inflammatory state
Favorable
Nutritional resilience
Declining
Discontinuation risk
22%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 META-24 started — Baseline state S14
What changed?
Trajectory is tracking the baseline prediction.
Primary contributors, last 14 days
- Nutritional resilience-5
- Treatment adherence-5
- GI instability+3
- Inflammatory activity-2
What helped?
No interventions yet.
LIFE OS recommendation
No intervention is indicated right now. The trajectory is stable relative to similar patients. See what worked for similar patients.
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
Active minutes
Wearable76 min
stable · -1.1 vs previous 14 d
Sleep duration
Wearable8.1 h
stable · +0.1 vs previous 14 d
Energy level
Daily log7.4/10
stable · +0.1 vs previous 14 d
Steps
Wearable8,218
stable · +147 vs previous 14 d
GI burden
Companion5.8/100
improving · -3.1 vs previous 14 d
Adherence
Companion90.9 %
stable · +0.3 vs previous 14 d
Sleep quality
Wearable68.7/100
stable · +0.8 vs previous 14 d
Glucose, CGM daily mean
CGM118 mg/dL
stable · -1.3 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →Heading towards failing · 100 from the failing basin, 15 from restoration.
Would help
- No untried action with strong evidence. Compose one from primitives.
- More proteinGI -6.2 next day on high-intake days · n 17
- More caffeineGI -3 next day on high-intake days · n 17
Would not help
- Keep ultra-processed lowGI +4.7 next day on high-intake days · n 16
- Keep histamine lowGI +3.9 next day on high-intake days · n 18
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Protein-6.2supporter · 95%
- Ultra-processed food+4.7detractor · 95%
- Histamine load+3.9detractor · 95%
- Caffeine-3supporter · 64%
- Simple carbohydrates-2.8supporter · 57%
- Dietary fat load-1.7no signal · 33%
- Insoluble fibre-0.5no signal · 15%
- Alcohol-0.1no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Mucosal barrier integrity ↓30
- DNAFUT2 non-secretor lowers mucosal fucosylation
- Inflammatory signalling ↓25
- DNAIL6 -174 variant raises baseline inflammatory tone
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Rapid metabolizerExpected exposure
- GLP1R rs6923761 AAltered receptor sensitivity
- MTHFR C677TReduced folate turnover
Microbiome
Shannon diversity 4.1 · butyrate capacity 61/100
- Akkermansia muciniphilaNormal
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisNormal
- Bifidobacterium longumLow
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 58 ms
- Sleep
- 8.2 h
- Steps
- 8,707
- Resting HR
- 62 bpm
Daily log: GI score 6, nutritional resilience 69, adherence 91.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Keep meals regular; three to four moderate portions spaced through the day
- Include a cooked vegetable portion with each main meal
- Keep fibre steady; no new sources this week
- Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
- Log the daily check-in; one line is enough
- Keep the current walking rhythm
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the dose at the same time relative to your evening meal
- No additional supplements this week
- Fictional demo item: continue vitamin D as before
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-02277 | 51% | S05 | AD-05 | improved | 92 |
| P-02486 | 50% | S10 | ME-01 | improved | 86 |
| P-02450 | 49% | S12 | NP-02 | improved | 92 |
| P-02630 | 45% | S17 | NP-02 | improved | 76 |
| P-02068 | 44% | S14 | NP-02 | improved | 83 |
| P-02249 | 43% | S09 | DT-01 | improved | 100 |
| P-02464 | 42% | S18 | ME-01 | improved | 68 |
| P-02667 | 42% | S08 | HY-01 | improved | 77 |
| P-02127 | 41% | S11 | SC-12 | improved | 73 |
| P-02415 | 41% | S17 | GI-04 | improved | 86 |
| P-02193 | 39% | S11 | CR-01 | improved | 87 |
| P-02690 | 38% | S02 | ME-01 | improved | 73 |